Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy.
Tafrali C, Paizi A, Borg J, Radmilovic M, Bartsakoulia M, Giannopoulou E, Giannakopoulou O, Stojiljkovic-Petrovic M, Zukic B, Poulas K, Stavrou EF, Lambropoulou P, Kourakli A, Felice AE, Papachatzopoulou A, Philipsen S, Pavlovic S, Georgitsi M, Patrinos GP.
Tafrali C, et al. Among authors: papachatzopoulou a.
Pharmacogenomics. 2013 Apr;14(5):469-83. doi: 10.2217/pgs.13.31.
Pharmacogenomics. 2013.
PMID: 23556445